GSK encourages research excellence as award nominations open

GSK has opened nominations for what is regarded as one of the most prestigious research awards available to the Australian science community - the 2014 GSK Award for Research Excellence (ARE).

The Award offers a grant of $80,000 and recognises outstanding achievements in medical research. It is now in its 34th year and has a proud history of supporting some of Australia’s most influential innovators in the medical research sector.

Past recipients include one of Australia’s top malaria researchers Professor Alan Cowman (1998) and world-leading Paediatric Neurologist Professor Kathryn North (2011). Last years’ winner was Professor Ingrid Scheffer whose clinical research has led to the recognition of several new epilepsy syndromes and the discovery of new causative genes in epilepsy.

According to GSK Medical Director Dr Andrew Yeates, the Award is consistent with GSK’s commitment to being a research-based company focussed on innovation.

“The work that GSK undertakes, our products and programs are the result of excellence and collaborations in medical research. As such, we acknowledge the commitment and resources needed in order to achieve innovations in the research arena. GSK looks forward to the positive outcomes generated from the research through the assistance from the Award,” said Dr Yeates.

The winner will be announced on 5 November 2014 at the 12th Annual Research Australia Awards night in Sydney.

Further information is available on the GSK ARE website. Please email any enquires to are.arenominations@gsk.com.

Nominations will close 30 June 2014.

This media release as been issued by Palin Communications on behalf of GSK.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

GSK collaborates with local researchers and doctors to discover new ways of treating and preventing disease, investing around $51 million a year in research and development.

Enquiries or interview requests please contact: